Bank of New York Mellon’s Palisade Bio PALI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$728K Buy
348,469
+335,557
+2,599% +$660K ﹤0.01% 3547
2026
Q1
$22.6K Hold
12,912
﹤0.01% 4174
2025
Q4
$30.3K Buy
+12,912
New +$24.8K ﹤0.01% 4154
2021
Q2
Sell
-10
Closed -$75K 4452
2021
Q1
$75K Sell
10
-1
-9% -$6.75K ﹤0.01% 4201
2020
Q4
$42K Hold
11
﹤0.01% 4164
2020
Q3
$28K Hold
11
﹤0.01% 4073
2020
Q2
$34K Hold
11
﹤0.01% 4021
2020
Q1
$31K Buy
+11
New +$47.6K ﹤0.01% 4020
2017
Q1
Hold
0
-$25K 4310
2016
Q4
Hold
0
4199
2016
Q3
Hold
0
4174
2016
Q2
Hold
0
4219
2016
Q1
Hold
0
3989
2015
Q4
Hold
0
4021
2015
Q3
Hold
0
3985
2015
Q2
Hold
0
3838
2015
Q1
Hold
0
3540
2014
Q4
Hold
0
3405
2014
Q3
Hold
0
3238
2014
Q2
Hold
0
3151
2014
Q1
Hold
0
3602
2013
Q4
Hold
0
3918
2013
Q3
Hold
0
4031

Other funds holding PALI

Bank of New York Mellon's PALI Position: Q2 2026 in Review

Bank of New York Mellon increased its Palisade Bio (PALI) stake by 2,599% in Q2 2026, buying an estimated $660K and bringing the position to 348,469 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #3547.

Bank of New York Mellon first reported a position in PALI in Q1 2020 and has held it in 8 quarters since. 31 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Bank of New York Mellon held 348,469 shares of Palisade Bio worth $728K as of Q2 2026.
  • Bank of New York Mellon bought 335,557 Palisade Bio shares in Q2 2026, an estimated $660K.
  • Palisade Bio made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3547 holding.
  • Bank of New York Mellon first reported a position in Palisade Bio in Q1 2020 and has held it in 8 quarters since.
  • 31 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.